The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
CSR Limited
Advised CSR Ltd, a leading building products manufacturer in Australia and New Zealand, on the divestment of its architectural glass manufacturing and processing business, Viridian
TeePublic
Advised Redbubble, a global online independent artist community and marketplace, on the acquisition of TeePublic, a similar online platform, and associated A$61 million equity raising
Uniseal, Inc.
Advised LG Chem, a global diversified chemicals manufacturer based in South Korea, on the acquisition of Uniseal, a US-based supplier of sealants and adhesives to leading automotive manufacturers
Montserrat Day Hospital Group
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
Nihon Nohyaku Co., Ltd.
Advised ADEKA Corporation, a global chemical manufacturer, on the acquisition of 51% stake of Nihon Nohyaku via the combination of the Tender Offer and Capital Injection
Suncorp Group Limited’s Australian Life Insurance Business
Advised TAL, Australia’s largest and leading insurance business that is 100% owned by Dai-ichi Life of Japan, on the acquisition of Suncorp Group Limited’s Australian Life Insurance business
Park Electrochemical (Electronics Business)
Advised Park Electrochemical, a leading high-performance electronics materials manufacturer, on the sale of its Electronics Business to AGC Inc.
GWA Group Limited’s Door and Access Controls Business
Advised Allegion plc, a leading global security products and solutions provider, on the acquisition of GWA Group Limited’s Door & Access Systems Business, a leading provider of door furniture and commercial locksmith services in Australia
Three Australia and New Zealand security businesses
Advised Anixter on its acquisitions of Central Security Distribution Pty Limited, Atlas Gentech (NZ) Limited and Inner Range Pty Limited
Crem International
Advised Welbilt, a leading global provider of commercial foodservice equipment on its acquisition of Crem International, a leading manufacturer of professional coffee machines
36.5% stake in DNV GL Group AS
Advised Det Norske Veritas Holding AS (“DNV”) on its acquisition of the 36.5% stake in DNV GL Group AS it did not already own from Mayfair Vermögensverwaltungs SE, whereby DNV is becoming the sole shareholder and regaining full control of DNV GL
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Godfrey Hirst
Advised Godfrey Hirst, the leading manufacturer, distributor and marketer of carpet and hard flooring in Australia and New Zealand, on its sale to Mohawk Industries, the NYSE-listed global flooring company
Jaybro
Advised Jaybro, a leading supplier of consumables to infrastructure contractors, on its sale to CHAMP Private Equity
Morris Corporation
Advised Morris Corporation, a leading independent player in Australia’s remote facilities management sector, on its sale to Sodexo SA, a France-based leading global facilities services company
Inenco Group Pty Ltd
Advised Inenco Group Pty Ltd, one of Australasia’s leading industrial distributors, on the partial sale to Genuine Parts Company, a global distributor of automotive and industrial products
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
US rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
US rights to 37 approved and 5 pipeline generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories